Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals — Q1 2025 Earnings Presentation

14 slides from Day One Biopharmaceuticals's earnings presentation, May 6, 2025

  1. Slide 1: First Quarter 2025 Financial Results & Corporate Progress

    MAY 2025 First Quarter 2025 Financial Results & Corporate Progress

  2. Slide 2: Forward looking statements

    Forward looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and unc

  3. Slide 3: Agenda & Day One Participants

    Agenda & Day One Participants Opening Remarks Jeremy Bender (Chief Executive Officer) OJEMDATM (tovorafenib) Lauren Merendino (Chief Commercial Officer) Financial Performance Charles York (Chief Operating & Chief Financial Officer) Q&A Session All, joined by: Elly Barry (Chief Medical Officer)

  4. Slide 4: Opening Remarks

    Opening Remarks Jeremy Bender Chief Executive Officer

  5. Slide 5: First quarter 2025 highlights

    1 OJEMDA received U.S. FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma on April 23, 2024. 2 Represents cash, cash equivalents and short-term investments as of March 31, 2025. First quarter 2025 highlights Financial Position $87.7M in net product revenue si

  6. Slide 6: OJEMDA Launch Performance

    OJEMDA Launch Performance Lauren Merendino Chief Commercial Officer

  7. Slide 7: Commercial performance by the numbers

    Commercial performance by the numbers $87.7M OJEMDA Net Product Revenue Since Launch1 $30.5M Q1 2025 OJEMDA Net Product Revenue 2,571 Cumulative Prescriptions Since Launch1,4 1 OJEMDA received U.S. FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma on April 2

  8. Slide 8: Continued OJEMDA revenue growth in Q1 2025

    ¹OJEMDA received U.S. FDA accelerated approval for relapsed or refractory BRAF-altered pediatric low-grade glioma on April 23, 2024. 2Q4 2024 revenue included approximately $1.4M of revenue associated with Ex-US sales which has been removed for the purposes of calculating quarter over quarter recurr

  9. Slide 9: Prescriptions Since Launch

    Prescriptions Since Launch 2 OJEMDA Prescriptions (TRx)1 +16% Strong commercial execution led to continued OJEMDA prescription growth in Q1 2025 Achieved 2,571cumulative scripts since launch Prescription Highlights Growth was driven by new patient starts and a high percentage of on-label patients co

  10. Slide 10: OJEMDA has significant patient opportunity across priority centers

    ~230 pLGG Patients* per Center PRIORITY 1 17 centers OJEMDA has significant patient opportunity across priority centers PRIORITY 2 85 centers PRIORITY 3 110 Centers ~5,000 ~4,000 ~4,000 Estimated total patients managed by priority 1 centers Estimated patients managed by priority account is calculate

  11. Slide 11: OJEMDA priorities to drive revenue growth in 2025

    OJEMDA priorities to drive revenue growth in 2025 r/r, relapsed or refractory. Drive depth of prescribing with current prescribers Encourage non-user HCPs to try OJEMDA in their next r/r pLGG patient Establish OJEMDA as standard of care in 2nd line relapsed or refractory BRAF-altered pLGG Support pr

  12. Slide 12: Financial Performance

    Financial Performance Charles York Chief Operating Officer & Chief Financial Officer

  13. Slide 13: First quarter 2025 financial results

    All financial information is unaudited. 1 Includes stock-based compensation expense of $4.3 million for the three months ended 3/31/25, and $4.7 million for the three months ended 3/31/24. 2 Includes stock-based compensation expense of $8.6 million for the three months ended 3/31/25, and $8.0 millio

  14. Slide 14: Thank You

    Thank You

Day One Biopharmaceuticals — Q1 2025 Earnings Presentation on 6ix